It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Cases in which bilateral adrenal 123I-Metaiodobenzylguanidine (123I-MIBG) scintigraphy accumulation is sometimes shown, with mildly elevated catecholamine (CA) or metanephrine (MN) levels (within 3 times the upper reference limit) are diagnostic dilemmas. We experienced 3 cases of adrenal incidentalomas with this dilemma in the differential diagnosis. The clinical diagnosis was subclinical Cushing's syndrome in 2 cases, and primary aldosteronism in 1. Despite suspected CA excess in clinical symptoms and imaging findings, the pathological findings of all these tumors were revealed to be cytochrome P450 family 11 subfamily B member 1 (CYP11B1) positive adrenocortical adenomas. Interestingly, adrenal medullary hyperplasia (AMH) was detected in the adrenal parenchyma of all those backgrounds. To clarify the clinical features of such cases, a cross-sectional study was conducted at the Kobe University Hospital from 2014 to 2020. One-hundred sixty-four patients who had undergone 123I-MIBG scintigraphy were recruited. Among them, 10 patients (6.1%) met the above criteria, including the presented 3 cases. Plasma adrenaline, noradrenaline, urinary metanephrine, and normetanephrine had values of 0.05 ± 0.05 ng/mL, 0.63 ± 0.32 ng/mL, 0.22 ± 0.05 mg/day, and 0.35 ± 0.16 mg/day, respectively. Nine cases were complicated with hypertension, and symptoms related to CA excess were observed. Half of them (5 cases) including presented 3 cases had unilateral adrenal tumors. These suggest that in cases of bilateral adrenal uptake on 123I-MIBG, AMH needs to be considered. Adrenocortical adenomas may be associated with AMH and further larger investigation is needed for this pathology.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Kobe University Hospital, Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe, Japan (GRID:grid.411102.7) (ISNI:0000 0004 0596 6533); Osaka Medical and Pharmaceutical University, Department of Internal Medicine(I), Takatsuki, Japan (GRID:grid.411102.7)
2 Kobe University Hospital, Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe, Japan (GRID:grid.411102.7) (ISNI:0000 0004 0596 6533)
3 Kobe University Graduate School of Medicine, Division of Diabetes and Endocrinology, Kobe, Japan (GRID:grid.31432.37) (ISNI:0000 0001 1092 3077)
4 Kobe University Hospital, Department of Diagnostic Pathology, Kobe, Japan (GRID:grid.411102.7) (ISNI:0000 0004 0596 6533)
5 Tohoku University Hospital, Department of Pathology, Sendai, Japan (GRID:grid.412757.2) (ISNI:0000 0004 0641 778X)
6 Kobe University Graduate School of Medicine, Department of Radiology, Kobe, Japan (GRID:grid.31432.37) (ISNI:0000 0001 1092 3077)
7 Kobe University Graduate School of Medicine, Division of Urology, Department of Organ Therapeutics, Faculty of Medicine, Kobe, Japan (GRID:grid.31432.37) (ISNI:0000 0001 1092 3077); Kobe University Graduate School of Health Science, Department of Public Health, Kobe, Japan (GRID:grid.31432.37) (ISNI:0000 0001 1092 3077)
8 Kobe University Graduate School of Medicine, Division of Diabetes and Endocrinology, Kobe, Japan (GRID:grid.31432.37) (ISNI:0000 0001 1092 3077); Kobe University Graduate School of Medicine, Division of Development of Advanced Therapy for Metabolic Disease, Kobe, Japan (GRID:grid.31432.37) (ISNI:0000 0001 1092 3077)
9 Kobe University, Medical Center for Student Health, Kobe, Japan (GRID:grid.31432.37) (ISNI:0000 0001 1092 3077); Kobe University Graduate School of Medicine, Department of Biosignal Pathophysiology, Kobe, Japan (GRID:grid.31432.37) (ISNI:0000 0001 1092 3077)
10 Tohoku Medical and Pharmaceutical University, Division of Pathology, Sendai, Japan (GRID:grid.412755.0) (ISNI:0000 0001 2166 7427)
11 Kobe University Graduate School of Medicine, Division of Urology, Department of Organ Therapeutics, Faculty of Medicine, Kobe, Japan (GRID:grid.31432.37) (ISNI:0000 0001 1092 3077)
12 Osaka Medical and Pharmaceutical University, Department of Internal Medicine(I), Takatsuki, Japan (GRID:grid.31432.37)